Printer Friendly

BONE HEALTH INC. WARRANTS EXTENDED TO SEPT. 30, 1993

 TORONTO, April 1 /PRNewswire/ -- Bone Health Inc. (NASDAQ: BNHWF), a Canadian corporation, today announced that its warrants have been extended to Sept. 30, 1993. Each warrant entitles the holder until Sept. 30, 1993, either to purchase one common share of Bone Health for Cdn $0.30 or to redeem the warrant for Cdn. $0.20.
 Bone Health is in the process of completing its due diligence review of an analysis by Bone Care International, Inc. of the final data from the clinical studies conducted at Creighton University in Omaha, Neb., regarding One-alpha D2, a drug for use in the treatment of osteoporosis. Because the due diligence review and assessment of prospects for One-alpha D2 is time consuming, Bone Health believes that the extension is necessary to allow warrant holders enough time to receive further information and to make an informed investment decision on their warrants. Following appropriate filings with securities regulatory authorities both in Canada and the United States, Bone Health will distribute a complete final prospectus to all warrant holders, as permitted by law, setting forth Bone Health's intentions regarding One-alpha D2.
 Bone Health Inc., a wholly owned subsidiary of Deprenyl Research Limited, is a newly formed Canadian corporation, established to develop products including pharmaceutical prescription products for the Canadian market for the treatment of bone diseases, and in particular osteoporosis.
 -0- 4/1/93
 /CONTACT: Deborah Worobec of Bone Health, 416-537-4372, or fax, 416-537-1653; or Jim Tolan of O'Connor Biro & Associates, 708-498-2284, or fax, 708-498-3144, for Bone Health/
 (BNHWF)


CO: Bone Health Inc. ST: Ontario IN: MTC SU:

CK -- NY122 -- 2271 04/01/93 17:27 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 1, 1993
Words:269
Previous Article:HOTEL INDUSTRY URGES NEW YORK STATE LEGISLATURE TO REPEAL HOTEL TAX NOW
Next Article:MERRILL LYNCH $150 MILLION NOTES RATED 'AA-' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
DEPRENYL RESEARCH ANNOUNCES FINAL PROSPECTUS OF BONE HEALTH INC.
DEPRENYL USA ANNOUNCES NO CHANGE AT COMPANY TO ACCOUNT FOR SHARE PRICE PRESSURE
DEPRENYL RESEARCH LTD. & BONE HEALTH INC. TO AWAIT FULL ANALYSIS OF CLINICAL TRIALS BEFORE ISSUING FINAL AMENDMENTS TO PROSPECTUS
LUNAR ANNOUNCES THAT ONE-ALPHA D2 WAS EFFECTIVE
BONE HEALTH INC.: INDEPENDENT ANALYSIS OF ONE-ALPHA D2 TO BE COMPLETED
BONE HEALTH INC.: INDEPENDENT ANALYSIS OF ONE-ALPHA D2 TO BE COMPLETED
HEALTHCARE IMAGING SERVICES, INC. ANNOUNCES EXTENSION OF WARRANT EXERCISE PRICE REDUCTION PERIOD
DEPRENYL RESEARCH REPORTS EARNINGS
VIRATEK SUCCESSFULLY COMPLETES FINANCING: VIRATEK WARRANTS EXERCISED PROCEEDS EXCEED $14 MILLION
DURA PHARMACEUTICALS REPORTS OPERATING RESULTS FOR THIRD QUARTER AND FIRST NINE MONTHS OF 1993

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters